Thyrocare Technologies Limited (THYROCARE)
Please find attached the Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026
Press Release - Q1FY27
- Revenue 240.02 Cr +24% y-y; EBITDA 77.27 Cr +34% y-y; PAT 51.33 Cr +34% y-y
- Pathology segment revenue grew 26% YoY; franchise revenue +27%, partnership revenue +26%
- Processed 55.2 million tests, up 28% YoY, maintaining volume leadership
- Six Sigma quality with complaints down 24% YoY to 3.1 per million tests; ATAT 3.37 hours
- Expanded specialty diagnostics with Allergy and Genomics, focusing on clinical trust and quality
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 THYROCARE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add THYROCARE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Thyrocare Technologies Limited
Important.
The summary above is generated automatically from Thyrocare Technologies Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.